Evolent Health (NYSE:EVH) Announces Earnings Results

Evolent Health (NYSE:EVH) released its quarterly earnings results on Thursday. The technology company reported $0.02 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03, FiscalAI reports. The firm had revenue of $484.50 million during the quarter, compared to the consensus estimate of $597.69 million. Evolent Health had a negative return on equity of 3.94% and a negative net margin of 24.08%.The business’s revenue was up 46.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) EPS.

Here are the key takeaways from Evolent Health’s conference call:

• 2026 guidance was raised, with revenue now expected at $2.6 billion-$2.7 billion and adjusted EBITDA narrowed to $120 million-$135 million; full-year MER remains approximately 93%.
• Evolent announced a new oncology Performance Suite partnership covering approximately 1.5 million lives and expected to generate about $300 million in annualized revenue, pending regulatory approvals. The company also reported strong cross-selling activity with an existing Blue Cross customer.
• Management said Aetna and Highmark launches are showing clinical and provider engagement above expectations, while its AuthIntelligence AI platform has lifted auto-approval rates by up to 20 percentage points and now evaluates more than one-third of previously manual authorization volume.
• Evolent expects 2027 revenue growth above 25% and adjusted EBITDA of at least $150 million at the midpoint, supported by maturing Performance Suite contracts, cost reductions, productivity initiatives, and AI-related efficiencies.
• Near-term profitability remains affected by Highmark launch costs, expected Medicaid and exchange membership declines, and additional Performance Suite and AI investments. The company ended the quarter with $808.3 million of net debt and is evaluating capital-markets and strategic options to address 2029 maturities.

Evolent Health Stock Performance

Shares of EVH traded up $0.37 during mid-day trading on Friday, reaching $3.96. The company’s stock had a trading volume of 5,080,277 shares, compared to its average volume of 3,862,496. Evolent Health has a 1-year low of $2.10 and a 1-year high of $10.08. The stock has a market cap of $445.20 million, a P/E ratio of -0.87 and a beta of 0.79. The business has a 50-day simple moving average of $4.75 and a two-hundred day simple moving average of $3.72. The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 2.46.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Durable Capital Partners LP acquired a new stake in Evolent Health during the 2nd quarter valued at $72,326,000. Rubicon Founders LLC acquired a new position in shares of Evolent Health in the third quarter valued at $49,204,000. 8 Knots Management LLC bought a new position in shares of Evolent Health in the second quarter valued at about $32,802,000. Goldman Sachs Group Inc. raised its position in shares of Evolent Health by 162.2% in the first quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock valued at $26,861,000 after purchasing an additional 1,754,520 shares during the period. Finally, Maverick Capital Ltd. lifted its stake in shares of Evolent Health by 6.0% during the 4th quarter. Maverick Capital Ltd. now owns 2,539,930 shares of the technology company’s stock worth $10,160,000 after buying an additional 144,646 shares during the last quarter.

Evolent Health News Summary

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Evolent reported second-quarter adjusted earnings of $0.02 per share, compared with analysts’ expectation of a $0.01 loss and a $0.10 loss in the year-ago quarter. Evolent Health Tops Q2 Earnings and Revenue Estimates
• Positive Sentiment: Quarterly revenue rose sharply year over year, with management emphasizing continued growth, improving profitability, and stronger cash flow. The earnings call also highlighted a bullish 2027 outlook, supporting the view that Evolent’s expansion is becoming more durable. Evolent Health Q2 2026 Earnings Call Highlights
• Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.6 billion to $2.7 billion, above the roughly $2.5 billion consensus estimate. That outlook gives investors greater confidence in Evolent’s growth trajectory. Evolent Announces Second Quarter 2026 Results
• Neutral Sentiment: Despite the improved operating performance, Evolent remains unprofitable on a GAAP basis, with a negative net margin, and analysts still project a full-year loss. Execution against the new guidance will therefore remain important.
• Negative Sentiment: The company continues to carry elevated leverage, including a debt-to-equity ratio above 2, which could limit financial flexibility if growth or cash-flow improvements fall short.

Analyst Ratings Changes

A number of equities analysts have recently commented on EVH shares. TD Cowen reduced their price objective on shares of Evolent Health from $8.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, July 28th. Weiss Ratings upgraded Evolent Health from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Truist Financial cut Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 price target for the company. in a research report on Tuesday, June 30th. Canaccord Genuity Group raised their price target on Evolent Health from $6.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Finally, Citigroup reaffirmed a “sell” rating and set a $6.75 price target (up from $5.50) on shares of Evolent Health in a research report on Thursday, July 23rd. Eleven analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $6.16.

About Evolent Health

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.